BCIQ Profiles

Company Profile Report
0825 Kinnate
BioCentury & Getty Images


Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

RA Capital leads round to advance two programs towards IND

A crossover-heavy syndicate for Kinnate’s series C suggests an IPO could be on the horizon.

Aug 26, 2020 | 1:42 AM GMT

The presence of half a dozen crossover investors in Kinnate’s $98 million series C round suggests an IPO could be the next financing for the precision oncology company. 

If it does go public this year before its

Read the full 835 word article

How to gain access

Continue reading with a
two-week free trial.